Carl A. Gregory

The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow.

One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues.

Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy.

An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction.

Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow.

Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation.

How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow.

Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental "niches" in culture: a two-stage hypothesis for regulation of MSC fate.

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs.

The promise of canonical Wnt signaling modulators in enhancing bone repair.

More progress defining the crosstalk between multiple myeloma and mesenchymal stem cells of the bone marrow.

Leukemia inhibitory factor secretion is a predictor and indicator of early progenitor status in adult bone marrow stromal cells.

The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.

Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs).

CD133 identifies a human bone marrow stem/progenitor cell sub-population with a repertoire of secreted factors that protect against stroke.

Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy.

Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

Assays of osteogenic differentiation by cultured human mesenchymal stem cells.

Potential of modulating Wnt signaling pathway toward the development of bone anabolic agent.

Human mesenchymal stem cell-derived matrices for enhanced osteoregeneration.

Bone regeneration with osteogenically enhanced mesenchymal stem cells and their extracellular matrix proteins.

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs.